By the end of the month, insurers and doctors will have to decide whether to continue covering treatments for the millions of people who have already lost coverage due to the Affordable Care Act.
The question is whether to cover treatments for a few drugs and the rest of the medicine.
The answer, for now, will depend on what’s happening with the insurers and the doctors.
For some, the question of which drugs to cover has already become a political minefield.
“I’m sure there’s a bunch of companies that are making that decision,” said John Hochberg, chief medical officer for the pharmaceutical company Allergan.
“There’s a lot of people saying, ‘We don’t want to take our insurance with us.
We’re going to keep our drugs under the ACA.'”
That may be true.
But for others, the answer may come down to what they can afford.
Some insurers and medical providers are paying for the drugs themselves.
Others have set up a drug-adverse-effects program, which covers some of the drug costs and helps insurers cover the rest.
That could leave some insurers in a difficult spot.
“The people who are going to be most impacted by this are the ones who can’t afford it,” said Mark Bresnahan, a senior policy analyst at Avalere Health, a firm that tracks drug prices.
“For people who can, they’re not going to see the savings they might otherwise.”
That’s not an unreasonable position to take, said Dr. Robert Wood, a professor of medicine at the University of Pittsburgh School of Medicine.
But the stakes are high.
For one thing, insurers could be forced to raise premiums.
“If you can’t get that kind of cash to cover it, you’re probably going to have a higher premium,” Wood said.
In that scenario, some insurers could choose to pay for the drug at the point of purchase rather than the pharmacy, and others might be forced into a market-based pricing model.
Those price increases could also hurt patients, since they would force them to wait longer to get the drug they need, or have their coverage cut off.
For insurers that do decide to cover the drugs, the uncertainty is likely to create more competition in the market.
The problem is that it’s hard to tell how far a particular drug will go into the market, and how many patients will be covered by it.
As the government continues to negotiate with insurers, it may find itself in a bind: Should the government cover a few more drugs and keep the others off the market?
Or should it keep some of those drugs off the markets and cover a bunch?
And what happens if the federal government decides to cover only a few?
That’s why there are plans in the works to help insurance companies manage the transition.
The ACA requires insurers to cover drugs that are used for chronic conditions such as arthritis, diabetes, and cancer.
But it doesn’t cover drugs used for treating other conditions such, heart disease, or diabetes.
The Department of Health and Human Services announced in October that it would allow insurers to continue to cover certain drugs, such as liposuction or insulin, for a period of five years after the first drug is no longer needed for people with serious conditions.
If the government decides in 2020 that these drugs are no longer necessary, insurers will be able to stop paying for those drugs.
The change would only apply to the cost of the first treatment, which is typically $300 to $400, and the cost for any subsequent treatments.
The government has also been considering allowing insurers to stop covering certain drugs for people who need a specific treatment, such to treat high blood pressure or diabetes or a rare disease.
That approach would not apply to medications that are needed to treat other conditions, such pain.
Under that approach, insurers would still be able cover those drugs, but they would have to pay a premium.
The process of getting a company to take on these new drugs has been a long one.
For decades, drug companies have been allowed to continue selling generic versions of their drugs, which typically include fewer side effects and are cheaper to manufacture.
But in 2015, the Food and Drug Administration decided to allow generic drugs to be sold in the United States.
The move came after several studies suggested that the newer, cheaper versions of these drugs could cause more serious side effects.
After the FDA made the change, the industry quickly began selling drugs that include generic versions, and they’re now being sold in a wide variety of states.
The new rules are meant to help reduce the number of drug-related lawsuits, but the government has acknowledged that it has no way of knowing how many companies are trying to avoid paying for these drugs, or how many of them are doing so to avoid getting sued.
The Obama administration has also warned insurers that they will be forced out of the market if they don’t take action.
Some of those insurers have already begun to